# Novadip Biosciences

> Regenerative-medicine biotech that raised €10.4 million of convertible financing to complete a pivotal Phase 3 trial.

## Why it is interesting

Late-stage clinical financing with a clearly disclosed convertible structure; useful for VCT's biotech database even though search demand is modest.

## Profile

- **Latest funding:** Convertible financing — €10.4M (September 21, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** New Science Ventures, Fund+, Wallonie Entreprendre, VIVES Fund

## Key facts

- Sep 21, 2026: €10.4M convertible financing
- Total convertible financing since June 2025: €20M

## Funding history

- Convertible financing · €10.4M · September 21, 2026
  Source: https://novadip.com/press-releases/novadip-secures-e10-4-million-financing-to-complete-pivotal-phase-3-trial/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/novadip-biosciences